Antares Pharma is a pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. Co. develops, manufactures and commercializes, for itself or with partners, therapeutic products using its drug delivery systems. Co.'s U.S. Food and Drug Administration (FDA)-approved products include XYOSTED® (testosterone enanthate) injection; NOCDURNA® (desmopressin acetate); and Sumatriptan Injection USP. Co. is also the supplier of devices to Teva Pharmaceutical Industries, Ltd. for their Epinephrine Injection USP. We show 48 historical shares outstanding datapoints in our ATRS shares outstanding history coverage, used to compute ATRS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ATRS market cap history over the course of time is important for investors
interested in comparing ATRS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ATRS versus a peer is one thing; comparing
ATRS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ATRS can fluctuate over the course of history.
With this page we aim to empower investors researching ATRS by allowing them to research the ATRS market cap history. |